• Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts
• ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms targeting renal and inflammatory diseases
• ZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 2022, which is expected to be completed in fourth quarter of 2022
• Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker “ZVSA”

ZyVersa Therapeutics, Inc. (“ZyVersa”), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop drug therapies that address unmet medical needs in the areas of renal and inflammatory diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR) (“Larkspur”), a blank-check special purpose acquisition company, are pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at BioFlorida’s 2022 Annual Conference being held in Miami, Florida on November 2-4, 2022.

Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the Experts. Mr. Glover will share his experience and insights in building an innovative and successful biopharmaceutical company.

The CEO Panel will take place:

• Date: Friday, November 4, 2022
• Time: 9:00 – 9:40am ET
• Event Registration Link: BioFlorida Annual Conference 2022

To learn more about ZyVersa, cholesterol efflux mediator (VAR 200), and inflammasome ASC inhibitor (IC 100), request a one-on-one meeting with Mr. Glover at ir@zyversa.com, or visit www.zyversa.com.